Document is current
Any future updates will be listed below
-
Authors
Mira-Pascual, Laia
Patlaka, Christina
Desai, Suchita
Paulie, Staffan
Näreoja, Tuomas
Lång, Pernilla http://orcid.org/0000-0002-3605-4014
Andersson, Göran
-
Funding
Funding for this research was provided by:
Marie Curie Initial Training Network (Euroclast, FP7-People-2013-ITN:#607447)
ERC FP7-Health-2007-A
Loo and Hans Osterman foundation
Maud Kuistila Memorial Foundation
Jane and Aatos Erkko Foundation
Swedish Research Council (#K2015-99X-10363-23-4, #2017-01083)
- License Information
-
More Information
Article History
Received: 17 May 2019
Accepted: 21 September 2019
First Online: 25 October 2019
Compliance with Ethical Standards
:
: For this study, Prof. Göran Andersson received research support from the Swedish Research Council, Dr. Staffan Paulie received research support from the European Research Council, and Dr. Tuomas Näreoja received research support from Jane and Aatos Erkko Foundation. Dr. Näreoja reports non-financial support from Mabtech Inc. during the conduct of the study. Dr. Staffan Pauli is a former CEO, shareholder, and current member of the board of directors of Mabtech Inc. The antibodies used in the study are considered for commercialization by Mabtech Inc. Laia Mira-Pascual, Christina Patlaka, Suchita Desaia, and Pernilla Lång declare that they have no conflict of interest.
: Human peripheral blood monocytes (hPBMC) were isolated from buffy coats of donated blood of healthy men at Karolinska University Hospital Laboratory, Huddinge, Sweden. The surplus blood products were coded for research use. The study was performed in accordance of guidelines from Swedish Research Council and Karolinska Institutet. All donors involved in the study gave written informed consent in accordance with the Helsinki Declaration.
